GH PEPTIDE PROTOCOLS: CJC-1295 + IPAMORELIN
The CJC-1295 no DAC and ipamorelin combination is the most widely used GH peptide protocol in the research community — for good reason. Here is the complete picture: mechanism, exact dosing, timing, what to expect week by week, and how to assess whether it is working.
1.Why the combination outperforms either alone
Growth hormone secretion requires the simultaneous convergence of two independent signals at the pituitary somatotroph cells: a GHRH signal (growth hormone releasing hormone) and a GHRP signal (growth hormone releasing peptide). These signals act through separate receptors — GHRH receptor and GHSR1a (ghrelin receptor) respectively — and their combined stimulation produces a synergistic GH pulse that exceeds either signal alone by a significant margin.
CJC-1295 no DAC is a GHRH analog — it mimics the natural GHRH signal from the hypothalamus. Ipamorelin is a GHRP — it provides the ghrelin receptor signal. Together, they drive both arms of the GH release mechanism simultaneously. This is not an additive effect — it is multiplicative. Human studies co-administering GHRH analogs with GHRPs show GH pulses 2-5x higher than either compound alone at equivalent doses.
The rationale for CJC-1295 no DAC specifically (rather than the DAC version): CJC-1295 without the drug affinity complex has a 30-minute plasma half-life. This creates a brief, pulse-like GHRH signal that mimics natural hypothalamic GHRH release. CJC-1295 with DAC has an 8-day half-life — it produces sustained GHRH elevation that creates continuous, non-pulsatile GH release. Most protocols favor the pulsatile pattern as more physiologically appropriate.
Ipamorelin versus GHRP-2 versus GHRP-6: GHRP-6 causes strong hunger spikes (useful for hardgainers who want to eat more, problematic for people cutting). GHRP-2 produces the highest GH pulse amplitude but also significantly elevates cortisol and prolactin — counterproductive for most goals. Ipamorelin produces clean GH release with minimal cortisol, prolactin, or appetite effects. For general body composition, recovery, and longevity goals, ipamorelin is the superior choice. GHRP-2 is substituted when maximum GH output is the overriding objective.
GHRH analogs and GHRPs can be drawn into the same insulin syringe and injected together in one subcutaneous injection. There is no chemical incompatibility, and the combined injection is far more practical than two separate injections for each dose.
2.Complete protocol: dose, timing, and duration
Standard beginner protocol: CJC-1295 no DAC at 100-150 mcg + ipamorelin at 200-300 mcg injected subcutaneously together, immediately before sleep, on an empty stomach. Empty stomach means no food or high-glycemic drinks for at least 2 hours prior. This is the most important single factor in protocol efficacy — insulin elevation blunts GH release significantly.
Advanced protocol (twice daily): Add a second injection upon waking, before any food, in addition to the pre-sleep injection. The morning injection taps into the natural morning GH pulse and can meaningfully increase total daily GH output. Twice-daily produces approximately 40-60% more total GH release than once-daily. Side effects (water retention, vivid dreams) are proportionally increased. Establish tolerance on once-daily for at least 4 weeks before adding the morning dose.
Duration: 112 days (16 weeks) is the standard recommendation for a first cycle with this combination. Shorter cycles (8 weeks) show effects but the body composition benefits accumulate over longer runs. After 16 weeks, take a 4-8 week off period before starting the next cycle to restore receptor sensitivity.
Dose escalation approach: some users start at the lower end of the range (100 mcg CJC + 200 mcg ipamorelin) for the first 4 weeks, then increase to 150-200 mcg CJC + 250-300 mcg ipamorelin for weeks 5-16 if the lower dose is well tolerated. This graduated approach reduces the intensity of initial side effects (water retention, vivid dreams) while the body adapts.
Storage and logistics: most users reconstitute a separate vial for each compound in their preferred concentration, then combine in the syringe at injection time. Some users pre-mix into a single vial, but this reduces flexibility for dose adjustment. Calculate concentrations so that the combined injection volume is manageable (0.1-0.3 mL) — this requires choosing concentrations accordingly.
3.Week-by-week expectations
Weeks 1-2: Sleep quality changes are reliably the first sign of an active protocol. Users describe deeper sleep, more vivid and memorable dreams, and a sensation of being more fully rested. Some notice slightly increased hunger, particularly around the 30-60 minute post-injection window. A mild 'pump' sensation upon waking is occasionally reported. These are all expected effects, not side effects.
Weeks 3-5: Water retention becomes apparent — typically as ring tightness in the morning, slight puffiness in the fingers and lower extremities. Body weight may increase 1-3 lbs from fluid. Some users notice early changes in skin texture and tone. The water retention can be temporarily reduced by limiting dietary sodium, but it partially reflects IGF-1-driven fluid regulation and partially resolves on its own as the body adapts.
Weeks 6-10: The body composition changes that most users are running this protocol for begin to manifest. Muscles appear harder and fuller. Recovery from resistance training measurably improves — soreness resolves faster, the ability to train at high intensity on consecutive days improves. Body fat, particularly visceral and subcutaneous abdominal fat, begins showing early reduction.
Weeks 10-16: Progressive and cumulative improvements in body composition. The most visible changes are often in the midsection and in the fullness and density of the major muscle groups. Sleep quality is consistently improved. Skin quality — firmness, texture, the 'glow' often described anecdotally — is a common observation at this stage. Users who photograph weekly see the most objective evidence of change.
Post-cycle and the off-period: when you stop the protocol, GH and IGF-1 return to baseline over 2-4 weeks. Water retention resolves (body weight may drop 2-4 lbs). Many users report that sleep quality remains improved for 2-4 weeks off-cycle before gradually returning to pre-protocol levels. Body composition changes made during the cycle are maintained if training and protein intake are sustained through the off period.
4.Monitoring and troubleshooting
IGF-1 blood testing is the most direct way to verify protocol efficacy. Baseline IGF-1, then test again at week 6-8. A working protocol at standard doses should raise IGF-1 by 30-100 ng/mL from baseline. If IGF-1 has not moved from baseline, the most likely culprits are: (1) insulin blunting from eating too close to injection, (2) insufficient dose, or (3) product quality issues.
Fasting glucose at week 6-8 is the primary safety check for this protocol. GH elevation reduces insulin sensitivity. If fasting glucose has risen above 100 mg/dL from a lower baseline, or by more than 10 mg/dL from a normal baseline, reduce the dose and retest in 3 weeks. Continuing a GH peptide protocol with rising fasting glucose is not appropriate without medical supervision.
Water retention that becomes uncomfortable or cosmetically unacceptable: first, reduce sodium intake. If that does not help within 2 weeks, reduce dose by 25-30%. Water retention typically correlates with IGF-1 levels — if your IGF-1 is at the high end of normal or above, reducing dose brings it in range and reduces water retention. Do not use diuretics to manage GH peptide-related water retention — address the root cause (IGF-1 level) instead.
Tingling or mild numbness in the hands or wrists (similar to early carpal tunnel syndrome) is a known GH-elevation side effect driven by fluid retention causing nerve compression. It is expected to resolve off-cycle. If it persists past 8 weeks on-cycle or becomes severe, reduce dose. True carpal tunnel progression from GH peptides at moderate doses is uncommon.
Vivid dreams are a reliable and expected effect of pre-sleep GH peptide injection. They indicate that slow-wave sleep architecture is being enhanced — which is actually the primary mechanism by which GH release improves. If they become distressing or prevent restful sleep (some users find the intensity too much), shifting injection timing from immediately before sleep to 30-60 minutes before sleep may reduce intensity.
Sources & Studies
Teichman SL. et al., J Clin Endocrinol Metab, 2006
Raun K. et al., Eur J Endocrinol, 1998
Corpas E. et al., Endocr Rev, 1993